Second, on the experimental equipment is to understand, and you think that you know well for 300-208 exam demo the whole industry products, in fact this is a 300-208 exam demo common one 300-115 study guides of the students psychology, we are only in their own in the sky, coming and going to know some 300-208 exam demo clients 200-105 exam are very diverse 300-208 exam demo equipment, customer project 200-105 exam to do and you can also ask some other questions, you 300-208 exam demo can it 200-105 exam just say I am a good the device is very good, 300-115 study guides and do it ask 200-105 exam questions of other customers! And now most laboratory used cisco 300-115 study guides equipment, so todays China market, most are 200-105 exam using 300-115 study guides H3C and some other 200-105 exam manufacturers of products, cisco only 300-208 exam demo in rich units are used. Not every company can use 300-208 exam demo cisco's equipment. So at the time of learning, not only to see your own lab equipment, but to get a comprehensive 300-115 study guides understanding 200-105 exam of the industry 300-115 study guides as a whole dynamic, 200-105 exam so whatever you do pre-sale, have 200-105 exam know, encounter similar equipment, can be solved, give customers a good impression. Third there are 300-208 exam demo some 300-208 exam demo people who always talk about advanced technology with 300-115 study guides others on the Internet, 200-105 exam saying that the 300-115 study guides questions they ask are rubbish and they 200-105 exam think they are as good 300-115 study guides as cows. Actually a 300-208 exam demo real player, a real ability, general it 300-115 study guides casually on the net, promote 200-105 exam their abilities are very modest, generally people ask questions, in the 300-208 exam demo case of time, will patiently answer, this is the difference. I met a lot of cool people, and everyone is modest and answers questions in 200-105 exam a way that is really 200-105 exam 300-208 exam demo cool. Fourth, there are some 300-208 exam demo people that I 300-208 exam demo took the CCNP certificate, why so low salary, 300-208 exam demo pay is what others so 300-208 exam demo high, and do the 300-115 study guides sample, I can only say, 300-115 study guides can only say that your ability not line, I been a technical director in a company, with others said so 200-105 exam in a word, do it envy other people have the ability 300-115 study guides to without you, but somebody else or your 300-115 study guides boss, can only say that your 300-115 study guides ability not 200-105 exam line, you just see 300-115 study guides the somebody else is insufficient place, did it see somebody else is advantages, so appear this kind of mentality.

A Warm Welcome From TNBC Foundation Scientific Advisor Lisa A. Newman 2017-04-04T17:43:34+00:00

A Warm Welcome From TNBC Foundation Scientific Advisor Lisa A. Newman

Lisa NewmanLisa A. Newman, MD, MPH, FACS
Director, Breast Care Center
Professor of Surgery
University of Michigan Comprehensive Cancer Center

Presentation on TNBC by TNBC Foundation Scientific Advisor Dr. Lisa A. Newman

For more than twenty years I have had the privilege of being able to care for thousands of patients with breast cancer and to study high-risk patterns of this disease that are associated with African ancestry. This work has led me to develop exciting collaborative relationships as well as friendships with diverse communities and medical professionals both here in the United States and in Africa. I love being able to tell my students and trainees with absolute sincerity that I wake up every day feeling blessed to have the greatest job in the world!

Over the course of my career I have witnessed a great many phenomenal advances in the detection and treatment of breast cancer, resulting in millions of survivorship stories throughout the world. It is an honor to have had opportunities to participate in the research that has fueled these advances, and it has moved me beyond anything that words can adequately express to see the courage and fervor with which my patients have battled their disease while also participating in this research. Fighting breast cancer involves a partnership between patients, their families, and health care providers as well as researchers and the advocacy community.

The entirety of my professional life has been characterized by repeatedly experiencing the full spectrum of emotional highs related to treatment success as well as the low points and heartbreak related to disease relapse and mortality. One of our most important areas of breast cancer research and discovery is the identification of breast cancer subtypes, with improved insights regarding the heterogeneity of this disease, which was previously approached with the “one size fits all” treatment paradigm. We have learned that our treatments are most effective and less toxic when they are tailored to the tumor biology of the individual patient. Unfortunately however, one particular pattern or subtype has remained elusive in our efforts to provide appropriate, targeted therapy. This pattern is widely known as triple negative breast cancer (TNBC), because these tumors fail to express the three microscopic markers for which “targeted” therapy is available. Hence, women diagnosed with TNBC face the immediate disadvantage of having a disease pattern for which therapeutic options are more limited. Furthermore, TNBC tumors tend to have an inherently more aggressive biology, enabling them to metastasize more rapidly than other subtypes. These lesions account for a minority (approximately 15%) of all breast cancers that we diagnose in the United States, but because they are more common among young breast cancer patients, they account for a disproportionately excessive loss of life among women in the prime of their professional and personal/childraising years. These cancers are twice as common among African American women. Hence, they also play a role in explaining the well-documented race/ethnicity-associated breast cancer disparities that are observed in this country, with African American women experiencing substantially higher breast cancer mortality rates compared to White American women. For these many reasons it is therefore imperative that we learn more about the causes of TNBC, and that we identify better ways to detect as well as treat these cancers.

My research has involved the study of breast cancer in populations that share ancestry with contemporary African Americans, and I lead a group of investigators at the University of Michigan in collaboration with health care providers at the Komfo Anoyke Teaching Hospital in Kumasi, Ghana. Ghana is located in western, sub-Saharan African, and was therefore a major site in the colonial-era slave trade. We have learned the TNBC accounts for a majority of the breast cancers in this region, leading us to speculate that African ancestry may be associated with a heritable marker placing women at increased risk for TNBC. This research has also generated novel information regarding breast cancer markers that are more common in TNBC tumors, and which are likely to be useful in targeted therapy of the future. Breast cancer disparities research here in the United States and in Africa is therefore a unique and powerful opportunity to learn more about the causes and improved treatments for TNBC, a disease that devastates women and families around the world, with a disproportionately negative impact on young women.

It was therefore a true highlight of my career when I had the pleasure of meeting the extraordinary Ms. Malaak Compton-Rock and learning about the Triple Negative Breast Cancer Foundation in October of 2008. We actually met halfway around the world, at a breast cancer conference in Ghana. I had of course already known of this remarkable young woman and her passionate yet focused drive to eliminate a variety of injustices in our global society, but being able to actually speak with her in person and learn about the incredible work of the TNBC Foundation was transformative! To see a group of advocates that were inspired and dedicated to fund research efforts aimed at TNBC was nothing less than amazing. One of my proudest achievements was being asked to serve on the medical advisory board for the TNBC Foundation, and I look forward to a longstanding partnership with this great organization as they continue funding research that will enable us to conquer this devastating pattern of breast cancer.

To the brilliant, visionary leadership of the Triple Negative Breast Cancer Foundation: I pledge my unending energy to working with you in seeking a cure. I commend you for your effort to reach out to the African American triple negative population as it is disproportionately affected by this disease. Through this website, its discussion forums, and the TNBC Helpline, the Foundation offers a great many resources to patients and their families from the point of diagnosis through treatment and beyond. To our African American sisters: I sincerely hope that you will continue to utilize these resources in your fight against TNBC. I thank you for being such brave and beautiful role models. You inspire all of us; you remind us to value and cherish every day of our lives as a blessed gift.